Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. by Tan, Jerry et al.
Masthead Logo
Thomas Jefferson University
Jefferson Digital Commons
Department of Dermatology and Cutaneous
Biology Faculty Papers
Department of Dermatology and Cutaneous
Biology
6-1-2019
Randomized phase 3 evaluation of trifarotene 50
μg/g cream treatment of moderate facial and
truncal acne.
Jerry Tan
Diane Thiboutot
Georg Popp
Melinda Gooderham
Charles Lynde
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/dcbfp
Part of the Dermatology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Dermatology and Cutaneous Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Authors
Jerry Tan, Diane Thiboutot, Georg Popp, Melinda Gooderham, Charles Lynde, James Del Rosso, Jonathan
Weiss, Ulrike Blume-Peytavi, Jolanta Weglovska, Sandra Johnson, Lawrence Parish, Dagmara Witkowska,
Nestor Sanchez Colon, Alessandra Alió Saenz, Faiz Ahmad, Michael Graeber, and Linda Stein Gold
Randomized phase 3 evaluation of
trifarotene 50 mg/g cream treatment of
moderate facial and truncal acne
Jerry Tan, MD,a Diane Thiboutot, MD,b Georg Popp, MD,c Melinda Gooderham, MD,d Charles Lynde, MD,e
James Del Rosso, DO,f Jonathan Weiss, MD,g Ulrike Blume-Peytavi, MD,h Jolanta Weglovska, MD,i
Sandra Johnson, MD,j Lawrence Parish, MD,k Dagmara Witkowska, MD,l Nestor Sanchez Colon, MD,m
Alessandra Alio Saenz, MD,n Faiz Ahmad, MS,n Michael Graeber, MD,n and Linda Stein Gold, MDo
Windsor, Peterborough, and Markham, Ontario, Canada; Hershey and Philadelphia, Pennsylvania;
Augsburg and Berlin, Germany; Las Vegas, Nevada; Snellville Georgia; Wrocław, Poland; Fort Smith,
Arkansas; San Juan, Puerto Rico; Fort Worth Texas; and Detroit, Michigan
Background: Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial
acne has not been rigorously studied.
Objectives: Assess the safety and efficacy of trifarotene 50 g/g cream, a novel topical retinoid, in
moderate facial and truncal acne.
Methods: Two phase III double-blind, randomized, vehicle-controlled, 12-week studies of once-daily
trifarotene cream versus vehicle in subjects aged 9 years or older. The primary end points were rate of
success on the face, as determined by the Investigator’s Global Assessment (clear or almost clear and $2-
grade improvement), and absolute change from baseline in inflammatory and noninflammatory counts
from baseline to week 12. The secondary end points were rate of success on the trunk (clear or almost clear
and $2-grade improvement) and absolute change in truncal inflammatory and noninflammatory counts
from baseline to week 12. Safety was assessed through adverse events, local tolerability, vital signs, and
routine laboratory testing results.
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Results: In both studies, at week 12 the facial success rates according to the Investigator’s Global
Assessment and truncal Physician’s Global Assessment and change in inflammatory and noninflammatory
lesion counts (both absolute and percentage) were all highly significant (P\ .001) in favor of trifarotene
when compared with the vehicle.
Limitations: Adjunctive topical or systemic treatments were not studied.
Conclusion: These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in
treatment of both facial and truncal acne. ( J Am Acad Dermatol 2019;80:1691-9.)
Key words: acne vulgaris; phase 3 trial; pivotal trials; trifarotene; truncal acne.
Acne vulgaris (AV) is one
of the most common skin
diseases, and it has a multi-
factorial pathogenesis that
centers on pilosebaceous
units.1,2 Because the patho-
physiology and clinical pre-
sentations of facial and
truncal acne are considered
to be similar, clinicians often
apply the same therapeutic
approach for facial and non-
facial lesions despite a lack of
evidence in truncal AV.3-5 A
variety of treatment options
are currently available for AV, but they have not been
rigorously studied in truncal disease.
Trifarotene 50 g/g cream is a new selective
retinoic acid receptor (RAR)-g (RARg) topical reti-
noid and is unique in that its clinical development
program included evaluation of performance in both
moderate facial and truncal acne. The selectivity of
trifarotene for RARg distinguishes it from the existing
first- and third-generation topical retinoids, which
target both RARb and RARg.6 Trifarotene is pharma-
cokinetically stable in keratinocytes but is rapidly
metabolized in hepatic microsomes, predicting a
favorable safety profile; in addition, it has comedo-
lytic, anti-inflammatory, and antipigmenting
properties. The primary efficacy results from 2
large-scale phase III studies (PERFECT 1 and
PERFECT 2 ClinicalTrials.gov registration number
NCT02566369 and NCT02556788, respectively, and
European Clinical Trials Database numbers 2016-
002860-15 and 2016-002540-13, respectively]) are
reported here.
METHODS
Study design
PERFECT 1 and PERFECT 2 were identical in
design and conducted in the United States, Canada,
Europe, and Russia from 2015 to 2017. Both studies
were 12-week, double-
blinded, multicenter, and
vehicle controlled, with a
1:1 randomization pattern
(once-daily trifarotene
50 g/g or vehicle cream).
Randomization was stratified
by study center with use of
an interactive response tech-
nology system. The clinical
study was conducted accord-
ing to standard recognized
practices, as detailed in the
Supplemental Information
(additional details about the
methods and a complete disposition chart are avail-
able at http://dx.doi.org/10.17632/cfjst82z93.1).
Instruction was provided to all patients or care-
givers about how to apply a thin layer of the study
drug daily at bedtime on the face and self-reachable
trunk, including areas with no clinically evident
acne. Patients were also instructed to cleanse the
skin and not apply moisturizer 1 hour before or
1 hour after application of the study drug. Use of
moisturizer was encouraged from the initiation of
treatment. Investigators could reduce the frequency
of application to alternate days for a maximum of
2 weeks in the first 4 weeks following the baseline
visit, when needed to manage irritation.
Study participants
The eligibility criteria were patient age 9 years and
older, moderate facial acne (defined as an
Investigator’s Global Assessment [IGA] score of 3
on the face [$20 inflammatory lesions and $25
noninflammatory lesions]), and moderate truncal
acne (defined as a Physician’s Global Assessment
[PGA] score of 3 at screening and baseline [$20
inflammatory lesions and 20 to\100 noninflamma-
tory lesions on the areas of the trunk reachable for
self-application]). Accessible treated areas of the
trunk were defined for the study. The trunk anatomic
CAPSULE SUMMARY
d Trifarotene is a new retinoic acid
receptor gamma-geselective topical
retinoid cream formulation that is
suitable for use on the face and trunk.
d Trifarotene appears to be safe and
efficacious as treatment of moderate
acne on the face and trunk. Local
tolerability was acceptable and
manageable on the face and trunk.
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region assessment was predefined by a size-fitted T-
shirt (patent No. US00D758048S [approved June 7,
2016]). This ensured consistency for study assess-
ment areas throughout the study duration. For sub-
jects aged 9 to 11 years, the inclusion criteria
regarding truncal acne were optional owing to the
relative rarity of truncal involvement (comparedwith
facial involvement) in this age group.
The exclusion criteria were severe forms of acne;
more than 1 nodule on the face; more than 1 nodule
on the trunk; presence of acne cysts, beard, or facial
hair that could interfere with study assessments;
presence of tattoos that could interfere with study
assessments; uncontrolled or serious disease or
medical condition; clinically significant abnormal
laboratory values; known or suspected allergies or
sensitivities to the planned study drugs; and lactation
or intent to conceive during the study in women. In
addition, prohibited medication use and washout
periods of 1 to 4 weeks were specified for use of
antiacne treatments (prescription and over-the-
counter), nonsteroidal anti-inflammatory drugs, cor-
ticosteroids, and antibiotics (but 6 months for use of
oral retinoids and immunomodulators).
Efficacy and safety assessments
The 3 coprimary efficacy end points were rate of
success, as determined according to the IGA
(defined as the percentage of subjects who achieved
an IGA face rating of clear [0] or almost clear [1]) and
at least a 2-grade change from baseline) at week 12;
the absolute change in facial inflammatory lesion
count; and the absolute change in noninflammatory
lesion count from baseline to week 12. There were
also 3 secondary efficacy end points: rate of success,
as determined according to the PGA (defined as
percentage of subjects achieving a rating of clear or
almost clear on and at least a 2-grade change from
baseline) at week 12; absolute change in truncal
inflammatory lesion count from baseline to week 12;
and absolute change in truncal noninflammatory
lesion count from baseline to week 12. The defini-
tions of severity for the IGA and PGA scales (5-point
scales ranging from 0 [clear] to 4 [severe]) were the
same.
Lesion counts were performed, and IGA and PGA
scores were assessed at screening; at baseline; and at
the week 1, 2, 4, 8, and 12/early termination visits.
The safety assessments included treatment-
emergent adverse events (TEAEs); standard labora-
tory safety test results at screening; and results at the
last study visit, including the following: hematology,
blood chemistry, and urinalysis results (BARC
Central Laboratory, Lake Success, NY, and Gent,
Belgium); physical examination findings; and moni-
toring of vital signs. Local tolerability signs and
symptoms expected with a topical retinoid were
collected separately from adverse events (AEs) to
better characterize the tolerability profile of trifaro-
tene cream. These included erythema, scaling, dry-
ness, and stinging/burning, which were scored on a
4-point scale (according to which a score of 0 indi-
cated none, 1 indicated mild, 2 indicated moderate,
and 3 indicated severe). Subjects were specifically
queried at each study visit, including at baseline, for
the presence of local signs or symptoms. Signs and/
or symptoms of local cutaneous irritation assessed
with the tolerability scale were considered to be AEs
if they were severe enough to lead to permanent
discontinuation of treatment with the study product
or if they required use of concomitant treatment
(including over-the-counter products other than
moisturizers).
Statistical analysis
All efficacy end points, local tolerability, labora-
tory test results, and vital signs were summarized by
analysis visit. Categoric data were summarized by
frequency and percentage for each response cate-
gory, and the continuous data were summarized by
using means, medians, minimums, maximums, and
standard deviations. For composite end points, suc-
cess rates were analyzed via the Cochran-Mantel-
Haenszel methodology stratified by analysis center.
Changes in lesion counts were evaluated through
analysis of covariance using baseline counts, analysis
center, and treatment as factors. The same statistical
methods were used for the composite secondary end
points. Multiple imputation methodology was used
for missing values.
TEAEs, regardless of relationship to study medi-
cation, were tabulated and summarized by incidence
as application site or noneapplication site events.
Relationship to treatment was determined by the
investigator. Common AEs were defined as those
experienced by at least 1% of all patients. Laboratory
evaluations were summarized with the use of
descriptive statistics.
Abbreviations used:
AE: adverse event
AV: acne vulgaris
IGA: Investigator’s Global Assessment (facial
acne)
PGA: Physician’s Global Assessment (truncal
acne)
RAR: retinoic acid receptor
RARg: retinoic acid receptor-g
TEAE: treatment-emergent adverse event
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RESULTS
Subject disposition, demographics, and
baseline characteristics
In PERFECT 1, a total of 1524 subjects were
screened and 1208 were randomized; of the ran-
domized subjects, 612 received trifarotene cream
and 596 received vehicle. There were 72 discontin-
uations in the trifarotene arm and 61 in the vehicle
arm, and in both cases the discontinuations were
primarily due to withdrawal by the subject and loss
to follow-up. In PERFECT 2, a total of 1293 subjects
were screened and 1212 were randomized; of the
randomized subjects, 602 received trifarotene cream
and 610 received vehicle. There were 44 discontin-
uations in the trifarotene arm and 37 in the vehicle
arm, and in both cases they were primarily due to
withdrawal by the subject and loss to follow-up.
Demographic and baseline data are presented in
Table I. The treatment groups were similar, with an
even distribution of pediatric and adult subjects, no
significant sex differences, and primarily white sub-
jects with skin phototypes I to III.
Table I. Patient characteristics (intent-to-treat population)
Characteristic
PERFECT 1 PERFECT 2
Trifarotene
50 mg/g (n = 612)
Vehicle
(n = 596)
Overall
(N = 1208)
Trifarotene
50 mg/g (n = 602)
Vehicle
(n = 610)
Overall
(N = 1212)
Age, y
n 612 596 1208 602 610 1212
Mean (SD) 19.6 6 6.88 19.3 6 5.89 19.4 6 6.41 19.6 6 6.2 19.9 6 6.4 19.7 6 6.3
Median 17 18 18 18 18 18
(Min, max) (9, 58) (10, 50) (9, 58) (11.0, 49.0) (11.0, 46.0) (11.0, 49.0)
Age categories, n (%)
\18 y 314 (51.3) 278 (46.6) 592 (49.0) 276 (45.8) 294 (48.2) 570 (47.0)
$18 y 298 (48.7) 318 (53.4) 616 (51.0) 326 (54.2) 316 (51.8) 642 (53.0)
Sex, n (%)
Male 307 (50.2) 272 (45.6) 579 (47.9) 245 (40.7) 272 (44.6) 517 (42.7)
Female 305 (49.8) 324 (54.4) 629 (52.1) 357 (59.3) 338 (55.4) 695 (57.3)
Race, n (%)
White 508 (83.0) 484 (81.2) 992 (82.1) 565 (93.9) 554 (90.8) 1119 (92.3)
Black or African American 47 (7.7) 49 (8.2) 96 (7.9) 27 (4.5) 42 (6.9) 69 (5.7)
Asian 23 (3.8) 32 (5.4) 55 (4.6) 2 (0.3) 6 (1.0) 8 (0.7)
American Indian or Alaska
Native
11 (1.8) 5 (0.8) 16 (1.3) 1 (0.2) 2 (0.3) 3 (0.2)
Native Hawaiian or other
Pacific Islander
1 (0.2) 1 (0.2) 2 (0.2) 0 (0.0) 1 (0.2) 1 (0.1)
Multiple 8 (1.3) 10 (1.7) 18 (1.5) 2 (0.3) 2 (0.3) 4 (0.3)
Other 14 (2.3) 15 (2.5) 29 (2.4) 5 (0.8) 3 (0.5) 8 (0.7)
Ethnicity, n (%)
Hispanic or Latino 135 (22.1) 148 (24.8) 283 (23.4) 60 (10.0) 62 (10.2) 122 (10.1)
Not Hispanic or Latino 477 (77.9) 448 (75.2) 925 (76.6) 542 (90.0) 548 (89.8) 1090 (89.9)
Skin phototype, n (%)
Type I 31 (5.1) 34 (5.7) 65 (5.4) 36 (6.0) 37 (6.1) 73 (6.0)
Type II 197 (32.2) 182 (30.5) 379 (31.4) 274 (45.5) 249 (40.8) 523 (43.2)
Type III 233 (38.1) 227 (38.1) 460 (38.1) 233 (38.7) 248 (40.7) 481 (39.7)
Type IV 97 (15.8) 91 (15.3) 188 (15.6) 33 (5.5) 38 (6.2) 71 (5.9)
Type V 43 (7.0) 48 (8.1) 91 (7.5) 14 (2.3) 19 (3.1) 33 (2.7)
Type VI 11 (1.8) 14 (2.3) 25 (2.1) 12 (2.0) 19 (3.1) 31 (2.6)
Baseline disease characteristics, mean 6 SD
Facial inflammatory lesions 34.7 6 13.02 34.8 6 13.612 34.8 6 13.31 36.1 6 12.47 37.1 6 15.06 36.6 6 13.84
Facial noninflammatory
lesions
54.0 6 28.55 52.8 6 26.08 53.4 6 27.35 50.6 6 25.93 51.2 6 25.75 50.9 6 25.83
Trunk inflammatory lesions 36.9 6 17.89 35.6 6 16.70 35.3 6 17.32 39.0 6 16.16 39.1 6 17.41 39.1 6 16.80
Trunk noninflammatory
lesions
46.4 6 21.57 47.5 6 21.94 46.9 6 21.75 46.1 6 20.17 45.7 6 19.58 45.9 6 19.87
SD, Standard deviation.
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Efficacy
The results of all coprimary and cosecondary
efficacy assessments in both studies at week 12
were statistically significant (P \ .001) in favor of
trifarotene versus vehicle (Table II).
For the 1214 patients treated with trifarotene and
1206 treated with vehicle, the week 12 facial suc-
cess rates according to the IGA were 29.4% in
PERFECT 1 and 42.3% in PERFECT 2 (vs 19.5% and
25.7% for vehicle [P\ .001]); trifarotene had statis-
tically significant superior success rates at week 4
(PERFECT 1) and week 8 (PERFECT 2). Trifarotene
treatment achieved significantly superior reductions
in facial lesion counts as well, with statistical
differences apparent as early as weeks 2 and 1:
with trifarotene treatment, the mean absolute in-
flammatory lesion counts were reduced by19.0 and
24.2 (vs by 15.4 and 18.7 with vehicle [P \ .001])
and the mean absolute noninflammatory lesion
counts were reduced by 25.0 and 30.1 (vs by 17.9
and 21.6 with vehicle [P\ .001]). The 3 coprimary
end points from baseline to week 12 are shown in
Figure 1.
The secondary end points showing the treatment
effect on truncal acne from baseline to week 12 are
presented in Figure 2. At week 12, the rates of
success with trifarotene according to the truncal
PGA were 35.7% in PERFECT 1 and 42.6% in
PERFECT 2 (vs 25.0% and 29.9%, respectively for
vehicle [each P\ .001]). In both PERFECT 1 and 2,
trifarotene was statistically significantly superior in
achieving reductions in inflammatory and nonin-
flammatory lesions on the trunk starting by week 4
in PERFECT 1 and by week 2 in PERFECT 2. Rates of
success on the trunk were statistically significant for
trifarotene versus for vehicle starting at week 8 in
both studies.
Safety
Local tolerability. Local irritation related to
trifarotene cream was transient and consistent with
the known pattern of topical retinoid dermatitis (Fig
3); tolerability was better on the trunk than on the
face. Local tolerability signs and symptoms related to
trifarotene cream included erythema, scaling, dry-
ness, and stinging/burning. These were mostly mild
to moderate by investigator assessment, with few
being severe. For facial acne, a worst postbaseline
score of moderate local tolerability signs and symp-
toms compared with baseline was reported for up to
33.2% of patients (in PERFECT 1: erythema, 23.7%;
scaling, 21.4%; dryness, 23.0%; and stinging/
burning, 16.3%; in PERFECT 2: erythema, 33.2%;
scaling, 32.9%; dryness, 36.4%; and stinging/
burning, 24.9%) and severe for up to 10.0% of
patients (in PERFECT 1: erythema, 2.5%; scaling,
2.9%; dryness, 2.5%; and stinging/burning, 4.2%; in
Table II. Summary efficacy results
Face: Coprimary end points
PERFECT 1 PERFECT 2
Trifarotene cream Vehicle cream Trifarotene cream Vehicle cream
(n = 612) (n = 596) (n = 602) (n = 610)
IGA success 29.4%* 19.5% 42.3%* 25.7%
Inflammatory lesions
Mean absolute change from baseline 19.0* 15.4 24.2* 18.7
Mean % change from baseline 54.4%* 44.8% 66.2%* 51.2%
Noninflammatory lesions
Mean absolute change from baseline 25.0* 17.9 30.1* 21.6
Mean % change from baseline 49.7%* 35.7% 57.7%* 43.9%
Trunk: secondary end points
PERFECT 1 PERFECT 2
Trifarotene cream Vehicle cream Trifarotene cream Vehicle cream
(n = 600) (n = 585) (n = 598) (n = 609)
PGA success 35.7%* 25.0% 42.6%* 29.9%
Inflammatory lesions
Mean absolute change from baseline 21.4* 18.8 25.5* 19.8
Mean % change from baseline 57.4%* 50.0% 65.4%* 51.1%
Noninflammatory lesions
Mean absolute change from baseline 21.9* 17.8 25.9* 20.8
Mean % change from baseline 49.1%* 40.3% 55.2%* 45.1%
Intent-to-treat, multiple imputation; success defined as at least a 2-grade improvement and IGA/PGA rating of clear (0) or almost clear (1).
IGA, Investigator’s Global Assessment; PGA, Physician’s Global Assessment.
*P less than .001 versus vehicle cream.
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PERFECT 2: erythema, 10.0%; scaling, 6.8%; dryness,
7.1%; and stinging/burning, 7.6%). On the trunk, the
corresponding percentages of worst postbaseline
local tolerability signs and symptoms were moderate
for up to 23.2% of patients (in PERFECT 1: erythema,
14.6%; scaling, 10.8%; dryness, 11.3%; and stinging/
burning, 9.0%; in PERFECT 2: erythema, 23.2%;
scaling, 16.7%; dryness, 20.9%; and stinging/
burning, 12.9%) and severe for up to 7.2% of patients
(in PERFECT 1: erythema, 3.3%; scaling, 0.3%; dry-
ness, 1.2%; and stinging/burning, 3.0%; in PERFECT
2: erythema, 7.2%; scaling, 3.0%; dryness, 2.5%; and
stinging/burning, 5.7%). The scores reached
maximum severity at week 1 for the face and at
weeks 2 to 4 on the trunk; after these time points,
scores diminished.
AEs. Most TEAEs related to trifarotene were
cutaneous and occurred at the application site.
Severe AEs considered related to trifarotene therapy
were reported in 6 subjects (in PERFECT 1: 4 with
skin irritation, 1 with sunburn, and 1 with allergic
dermatitis) and 3 subjects (in PERFECT 2: 1 with
application site pain, 1 with application site erosion,
and 1 with application site irritation) versus none in
the vehicle group, but no AE was serious. AEs led to
discontinuation in 1.9% (PERFECT 1) and 1.2%
(PERFECT 2) of the those in the trifarotene cream
and in no patients in the vehicle group; these AEs
were most commonly application site irritation,
allergic dermatitis, and skin irritation. There were
no significant clinically relevant changes in vital
signs, physical examination findings, or laboratory
parameters. There were 4 pregnancies (0.2%) among
the 2420 patients (1 pregnant patient was exposed to
trifarotene cream and 3 were exposed to vehicle
cream). The subject exposed to trifarotene was lost
to follow-up.
DISCUSSION
The 2 large-scale phase III studies generated
independent and substantial evidence of the effi-
cacy and safety of trifarotene cream in moderate
Fig 1. Facial acne vulgaris: coprimary end point from baseline to week 12. Success according
to the facial Investigator’s Global Assessment (IGA) is defined as clear or almost clear and at
least a 2-grade improvement (intent-to-treat population; multiple imputation [MI]).
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facial and truncal acne. In both anatomic regions
(face and trunk), trifarotene cream was significantly
superior to vehicle in success rates and in reduction
of inflammatory and noninflammatory lesion
counts.
There is sparse literature for the prevalence and
treatment of chest and back acne despite it being a
very common condition. Truncal acne often
accompanies facial acne in adolescence, or it may
first occur in and, indeed, persist well into
adulthood.4 Truncal acne has been estimated to
occur in 56% of patients with acne, with only a
slightly higher predominance in males (55% vs
46%).7 Back acne, once thought to be a
predominantly male disease, has been shown to be
prevalent in females.6
The pathophysiologic mechanism of acne on the
chest and back is similar to that of facial acne and
centers on the physiology and properties of the
pilosebaceous unit.3,4,8 Both anatomic areas are
considered sebum-rich locations, although the
sebaceous follicles on the back have a histologic
appearance different from those on the face.8 Few
studies have evaluated drugs in the treatment of
truncal acne and there are no well-designed
comparative studies. Most studies have been small
in scale and not rigorously controlled.3,4 A review of
the sparse evidence of the treatment outcomes of
acne located in different anatomic regions has shown
varying responses to systemic therapy when the face
and trunk are involved.8 The onset of effect of
trifarotene 50 g/g cream versus that of its vehicle
was rapid, with significant reductions in both
inflammatory and noninflammatory lesion counts
seen as early as 1 week after treatment on the face
and as early as 2 weeks after treatment on the trunk.
This observation is consistent with the findings of a
12-month, long-term safety study of trifarotene
50 g/g cream, in which the success rate for the
face and trunk demonstrated a consistent continuous
clinical improvement over time and within the same
subject (separate analysis).9
Fig 2. Truncal acne vulgaris: secondary end points from baseline to week 12. Success rate
according to the Physician’s Global Assessment (PGA) of truncal acne is defined as a PGA score
of 0 or 1 and at least a 2-grade improvement. (intent-to-treat trunk population; multiple
imputation [MI]).
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Trifarotene had a manageable safety and tolera-
bility profile, with the majority of AEs being local
cutaneous irritation that beganmainly during the first
weeks of treatment and improved thereafter. Local
tolerability was better on the trunk than on the face.
Similar results were reported in a long-term safety
study of trifarotene.9 In the combined pool from both
studies, the local signs and symptoms for the face
and trunk that worsened after baseline (skin dryness,
erythema, scaling, stinging, and burning) were mild
to moderate in severity, with few subjects who
experienced severe tolerability problems. The im-
plementation of routine standard skin care, such as
use of noncomedogenic moisturizers and gentle
cleanser, and dosing regimen adjustments were
sufficient to ensure treatment management and
compliance in the majority of patients. There were
no relevant changes in laboratory safety test results
when trifarotene 50 g/g cream was applied to large
surface areas. Study limitations include absence of
well-established optimal regimens and dosing stra-
tegies for truncal acne. These two phase 3 studies
showed that once-daily trifarotene cream appears
effective and safe, with manageable local tolerability,
for the treatment for facial and truncal acne. The
studies provide substantial evidence to support use
of this new topical retinoid in facial and truncal acne.
CONCLUSIONS
Trifarotene 50 g/g cream appears to be effective
and safe in the treatment of moderate acne on the
face and trunk, meeting all primary and secondary
efficacy end points of 2 independent, randomized,
well-controlled studies. Trifarotene exhibited the
expected local tolerability profile of a topical reti-
noid. In both studies, the local tolerability profile of
trifarotene was mostly mild or moderate and
manageable when it was applied to the face as well
as to the larger body surface areas of the trunk.
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Fig 3. Tolerability profile of trifarotene and vehicle from baseline to week 12 in facial and
truncal acne. Severity scale score indicates: 0 (none), 1 (mild), 2 (moderate) and 3 (severe).
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